ALK and lymphoma: At the cellular level, brigatinib was shown to inhibit proliferation and intracellular ALK protein phosphorylation of AlK-driven lymphoma cells Karpas-299, SU-DHL -1, L-82, and SUP -M2 and lung cancer cells H3122 and NCLH2228.The results showed that 50 mg/kg brigatinib could lead to shrinkage or even complete regression of Karpas-299 and NCI-H2228 transplanted tumors in mice.